Aesthetic Performance and Tolerance of an Injective Intradermal Treatment for the Skin Roughness and Laxity of Back of the Hands

Skin Laxity Clinical Trial

Official title:

Interventional, Post-marketing, Local, Mono-centric Study for Evaluation of Aesthetic Performance and Tolerance of an Injective Intradermal Treatment for the Skin Roughness and Laxity of Back of the Hands

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05590364
• Other study ID #: E0122
• Status: Completed
• Phase: N/A
• Start date: November 7, 2022
• Est. completion date: June 8, 2023

Study information

• Verified date: November 2022
• Source: IBSA Farmaceutici Italia Srl
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

People lose collagen all over the body, not just in the face; skin roughness and laxity of the dorsum of the hands can result from chrono and photo-aging. This skin roughness and laxity can range from very mild to severe; injection procedures can provide new tone and firmness to the skin of the hand dorsum. Dermal fillers are the most used non-permanent injectable materials available today to correct skin flaccidity and roughness on the dorsum of the hands. They give immediate aesthetic effect due to elastic gel matrix injected and impart longer term effects due to bio stimulation, promoting new collagen formation. The objective of this study is to investigate the aesthetic performance of the Hyaluronic acid (HA)- based dermal filler Profhilo® Body injected by a blunt tip microcannula (25G or 22G, preferably 22G), with fanning technique through a single entry point performing 5 passages and injecting 0,3 ml per passage, 1,5 ml for each hand. Volunteers of both sexes, aged 18-65 years with mild-moderate skin roughness and laxity at the level of hand dorsum are to be treated.

Description:

Open, monocentric. 3 visits, 55 subjects. Primary endpoint of the study is the evaluation of performance and tolerance of Profhilo Body (3ml) treatment in the back of the hands ( or dorsum of the hands). Secondary endpoint is self-assessment questionnaire by both doctors and volunteers. Profhilo® Body (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 3.25 ml non-pyrogenic pre-filled syringe, containing 3 ml of 3.2% hyaluronic acid for intradermal use (48 mg H-HA + 48 mg L-HA) dissolved in 3 ml of saline buffered sodium chloride. - IBSA Farmaceutici Italia S.r.l. - ITALY. The principle component is cross-linked Hyaluronic Acid of non-animal origin, produced by bacterial fermentation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: June 8, 2023
• Est. primary completion date: June 8, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria: Will be included in the study volunteers with the following

characteristics:

• female and male sex, not necessarily 1:1 ratio;
• age 18-65 years;
• asking for hands restoration;
• available and able to return to the study site for the post-procedural follow-up examinations;
• accepting to not change their habits regarding food, physical activity, cosmetic and cleansing products for the hands;
• accepting not to expose their hands to strong UV irradiation (UV session, or sun bathes) during the entire duration of the study, without appropriate sun protection;

Exclusion Criteria:

• Pregnancy;
• lactation;
• smokers;
• alcohol or drug abusers;
• subjects not in menopause who do not use adequate contraceptive precautions in order to avoid pregnancies during the study;
• Body Mass Index (BMI) variation (± 1) during the study period;
• performing non-surgical skin aesthetic procedures for hands in the 6 months prior to the study start;
• aesthetic surgical procedure for the hands in the past;
• change in the normal habits regarding food, physical activity, cosmetic products and cleansing for the hands during the month preceding the test;
• sensitivity to the test product or its ingredients (to be assessed by the investigator during the baseline visit);
• subjects whose insufficient adhesion to the study protocol is foreseeable;
• participation in a similar study currently or during the previous 6 months.)
• presence of cutaneous disease on the tested area, as lesions, scars, malformations;
• clinical and significant skin condition on the test area (e.g. active eczema, psoriasis, sclerodermia, local infections).

Exclusion criteria due to systemic disease:

• Diabetes;
• endocrine disease;
• hepatic disorder;
• renal disorder;
• cardiac disorder;
• pulmonary disease;
• cancer;
• neurological or psychological disease;
• inflammatory/immunosuppressive disease;
• drug allergy Exclusion criteria due to ongoing pharmacological treatment
• Anticoagulants and antiplatelet drugs, anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago);
• using of drugs able to influence the test results in the investigator opinion. The use of other drugs, not mentioned above, can be authorized by the Investigator. The trade name, the dosage, the start and stop date of the therapy will be reported on concomitant medication form.

Related Conditions & MeSH terms

• Cutis Laxa
• Skin Laxity
• Skin Roughness

Intervention

Device:
• Profhilo® Body
Dosage form: Profhilo® Body (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 3.25 ml non-pyrogenic pre-filled syringe, containing 3 ml of 3.2% hyaluronic acid for intradermal use (48 mg H-HA + 48 mg L-HA) dissolved in 3 ml of saline buffered sodium chloride.

Locations

Country	Name	City	State
Italy	DERMING S.r.l., Clinical Research and Bioengineering Institute	Milano	Lombardia

Sponsors (2)

Lead Sponsor	Collaborator
IBSA Farmaceutici Italia Srl	Derming SRL

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline of Skin Roughness and flaccidity at 30 days and at 120 days post-injection	Visual score from 1 (no roughness and flaccidity) to 5 (very severe roughness and flaccidity)	Day 0, Day 30, Day 120
Primary	Change from Baseline of Skin density (profilometry) at 30 days and at 120 days post-injection	A picture of the skin is taken thanks to Primos compact portable device (GFMesstechnik) and a 3D representation is elaborated by Primos software.	Day 0, Day 30, Day 120
Primary	Change from Baseline of Superficial and deep skin plastoelasticity at 30 days and at 120 days post-injection	Measurement of the principal torsiometric parameters Ue (immediate extensibility), Uf (final extensibility), Uv (viscoelasticity) and Ur (immediate elastic recovery) by the instrument Dermal Torque Meter (Dia-Stron Ltd., UK)	Day 0, Day 30, Day 120
Primary	Change from Baseline of Tissue dielectric constant value of superficial and deep skin layers at 30 days and at 120 days post-injection	Non-invasive measurements of dielectric constant of the skin and subcutaneous fat by MoistureMeterD (Delfin Technologies, Kuopio - Finland). MoistureMeterD measures the changes in the total water content in the tissue with 0.5mm and 1.5mm probes.	Day 0, Day 30, Day 120
Primary	Change from Baseline of Photographic evaluation at 30 days and at 120 days post-injection	2D pictures of the dorsum of both hands are taken in order to support the aesthetic result assessment	Day 0, Day 30, Day 120
Secondary	Efficacy questionnaire	Self-assessment questionnaire regarding skin roughness and laxity of the treated areas, skin suppleness, skin smoothness, skin hydration, skin lifting, contour redefinition/remodeling (score: very marked; marked; medium; light; absent)	Day 30, Day 120
Secondary	Treatment tolerance questionnaire	Self-assessment score: bad; poor; good; excellent	Day 30, Day 120